NeOnc reports Phase 2a brain cancer trial results, plans FDA meeting

August 28, 2026 10:08 AM

NeOnc Technologies Holdings (NASDAQ: NTHI) reported positive topline results from its NEO100-01 Phase 2a clinical study in patients with recurrent ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found